Insider Transactions in Q4 2024 at Corcept Therapeutics Inc (CORT)
Insider Transaction List (Q4 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 27
2024
|
James N Wilson |
SELL
Bona fide gift
|
Indirect |
7,800
-0.59%
|
-
|
|
Dec 10
2024
|
Daniel N Swisher Jr |
SELL
Open market or private sale
|
Direct |
2,200
-100.0%
|
$129,800
$59.46 P/Share
|
|
Dec 10
2024
|
Daniel N Swisher Jr |
BUY
Exercise of conversion of derivative security
|
Direct |
2,200
+50.0%
|
$26,400
$12.13 P/Share
|
|
Dec 02
2024
|
William Guyer Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
309
-5.33%
|
$17,613
$57.68 P/Share
|
|
Dec 02
2024
|
Sean Maduck |
BUY
Grant, award, or other acquisition
|
Direct |
530
+0.31%
|
$15,370
$29.61 P/Share
|
|
Dec 02
2024
|
Sean Maduck |
SELL
Payment of exercise price or tax liability
|
Direct |
295
-0.35%
|
$16,815
$57.68 P/Share
|
|
Dec 02
2024
|
Joseph Douglas Lyon |
BUY
Grant, award, or other acquisition
|
Direct |
430
+2.43%
|
$12,470
$29.61 P/Share
|
|
Dec 02
2024
|
Joseph Douglas Lyon |
SELL
Payment of exercise price or tax liability
|
Direct |
165
-1.94%
|
$9,405
$57.68 P/Share
|
|
Dec 02
2024
|
Gary Charles Robb Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
580
+1.43%
|
$16,820
$29.61 P/Share
|
|
Dec 02
2024
|
Gary Charles Robb Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
324
-1.63%
|
$18,468
$57.68 P/Share
|
|
Dec 02
2024
|
Atabak Mokari Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
462
+1.79%
|
$13,398
$29.61 P/Share
|
|
Dec 02
2024
|
Atabak Mokari Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
182
-1.45%
|
$10,374
$57.68 P/Share
|
|
Nov 22
2024
|
Gary Charles Robb Chief Business Officer |
SELL
Bona fide gift
|
Direct |
300
-1.49%
|
-
|
|
Nov 22
2024
|
Gary Charles Robb Chief Business Officer |
SELL
Open market or private sale
|
Direct |
2,609
-11.46%
|
$146,104
$56.2 P/Share
|
|
Nov 22
2024
|
Joseph Douglas Lyon |
SELL
Open market or private sale
|
Direct |
1,411
-14.25%
|
$79,016
$56.72 P/Share
|
|
Nov 11
2024
|
Daniel N Swisher Jr |
SELL
Open market or private sale
|
Direct |
2,200
-100.0%
|
$129,800
$59.88 P/Share
|
|
Nov 11
2024
|
Daniel N Swisher Jr |
BUY
Exercise of conversion of derivative security
|
Direct |
2,200
+50.0%
|
$26,400
$12.13 P/Share
|
|
Nov 04
2024
|
William Guyer Chief Development Officer |
SELL
Open market or private sale
|
Direct |
3,394
-36.93%
|
$162,912
$48.97 P/Share
|
|
Nov 04
2024
|
William Guyer Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,394
+26.97%
|
$71,274
$21.65 P/Share
|
|
Nov 01
2024
|
William Guyer Chief Development Officer |
SELL
Open market or private sale
|
Direct |
6,606
-53.27%
|
$317,088
$48.97 P/Share
|
|
Nov 01
2024
|
William Guyer Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,606
+34.75%
|
$138,726
$21.65 P/Share
|
|
Oct 01
2024
|
William Guyer Chief Development Officer |
SELL
Open market or private sale
|
Direct |
10,000
-63.31%
|
$460,000
$46.28 P/Share
|
|
Oct 01
2024
|
William Guyer Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+38.77%
|
$210,000
$21.65 P/Share
|
|
Oct 01
2024
|
Gary Charles Robb Chief Business Officer |
SELL
Open market or private sale
|
Direct |
11,000
-32.57%
|
$506,000
$46.28 P/Share
|
|
Oct 01
2024
|
Gary Charles Robb Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,000
+24.57%
|
$33,000
$3.29 P/Share
|